Progressive Care Inc. Releases Shareholder Letter from CEO - Seite 3

Additional 2019 Key Highlights

• Completion of 2018 Audited Financial Statements
• Secured second acquisition: Family Physicians Rx (aka FPRx, FSRx)
• Over 450,000 prescriptions filled an increase of 54% (record)
• Over 45,000 prescriptions filled in a single month (record)
• Approx. $32 million in net revenues (record, and 56% year-over-year growth)
• 5-star rating
• Top 20% Pharmacy in the nation
• Highest Humana Scores in Company history (record)
• Six active Third-Party HealthCare Contracts (record)
• Increased not-for-profit healthcare claims to over $1 million per month (record)
• Processed over $7.5 million in claims on behalf of not-for-profit entities (record)
• Reached over 125 employees (record)
• Licensed in the following states: Colorado, Connecticut, Florida, Georgia, Illinois, Nevada, New Jersey, New York, Pennsylvania, Texas, Utah, Arizona, Massachusetts, Minnesota
• Contributed Articles published in prestigious online magazines: Forbes, Authority, HuffPost, and Fast Company

Outlook

Looking to the year ahead of us, we have a very ambitious agenda that will test us on many levels.

Upon completion of our 2019 audit, we intend to prepare a new S-1 filing for submission to the SEC. Our many accomplishments in 2019 have made previous drafts out-of-date. After registration with the SEC is complete, we will begin the process of uplisting to a national exchange. We believe that our development as a company now warrants that transition, which will provide us with access to a much larger, more diverse pool of prospective investors, including a much wider institutional investor audience.

We also look forward to further developing our contract services segment, targeting not-for-profit healthcare organizations. The robust growth we have seen in this domain now necessitates the development of a backend administration platform. We believe that our expertise in this area can lead to a significant new revenue stream that will allow us to further capitalize on our sophisticated data analytics capabilities even when we aren’t the dispensing pharmacy.

In addition, we established RXMD Therapeutics last year to deliver our own proprietary brands, including our exclusive line of CBD products. We do believe in the therapeutic benefits of CBD and continue to move forward on building our portfolio of products while we create the most efficient pathways for marketability.